arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Aclarion, Inc.

ACON
$2.26 ▼ -0.09 (-3.83%) at close
Healthcare ·Services-Medical Laboratories ·USServices-Medical Laboratories
6 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Bearish
auto_awesome

Analytical Summary

Aclarion, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.2M
Dividend Yield
Revenue Growth 65.6%
Op. Margin
ROIC -54.9%
FCF / Share $-13.51
Trailing P/E
Price / Book 0.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

6-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$75.73K
↑ +65.6%
Net Income Profit after all expenses
$-7.23M
↓ -3.4%
FCF / Share Free cash flow per share
$-13.51
↓ -4.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
15
Cash Quality
65

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 22 quarters